Actively Recruiting
Evaluating Oral Dotinurad for Adults With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Have Failed Uricase Treatment in a Randomized, Placebo-Controlled Phase 2 Trial
Led by Crystalys Therapeutics · Updated on 2026-09-28
90
Participants Needed
41
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy of dotinurad in lowering serum uric acid sUA levels in adults with gout who cannot tolerate xanthine oxidase inhibitors XOI or have failed uricase treatment. This Phase 2, randomized, double-blind, placebo-controlled study focuses on participants aged 18 to 75 with gout diagnosed for at least one year, assessing dotinurads ability to reduce sUA by Week 24. Participants are assigned to one of two groups one group receives dotinurad for 36 weeks, divided into a 24-week initial treatment period followed by a 12-week continuation. The other group takes placebo for the first 24 weeks and then switches to dotinurad for the final 12 weeks. Dotinurad is given orally as over-encapsulated tablets, while placebo capsules contain microcrystalline cellulose. This design allows comparison of dotinurad with placebo before all participants receive the active drug. During the study, participants undergo regular assessments including serum uric acid measurements at various timepoints up to Week 40. Researchers monitor the percentage of participants achieving target sUA levels, changes from baseline sUA, and treatment-emergent adverse events. Female participants of childbearing potential must have pregnancy tests and follow contraception requirements. The trial is expected to complete by August 2027, providing detailed safety and efficacy data over the treatment and follow-up periods.
CONDITIONS
Brief Title
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
Research Team
C
Clinical Trial Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here